Current Highlight from October 14, 2016
Sex Differences in Doxorubicin-Induced Cardiotoxicity
Scientists from NCTR, the National Cancer Institute, the Arkansas Heart Hospital, and Korea University have demonstrated an increased susceptibility to doxorubicin (DOX)-induced cardiac toxicity in adult male mice as compared to adult female mice, reflecting the differential toxicity noted in male and female cancer patients treated with DOX. Male mice exhibited greater myocardial damage than their female counterparts as evidenced by increases in cardiac troponin T levels in plasma, the development of cytoplasmic vacuolization in cardiomyocytes, and increases in apoptosis and DNA damage in the myocardium, particularly in the left atrium. This new mouse model has the potential to address biological mechanisms of DOX-induced cardiac injury and to identify sex-specific early biomarkers of DOX-induced cardiotoxicity. This may open avenues for ameliorating the toxicity of this highly effective anti-cancer drug. This publication is now available online at Toxicology and Applied Pharmacology.
For more information, please contact Varsha Desai, Ph.D., Division of Systems Biology, FDA/NCTR.
NCTR Research Highlights Archives
- 2016-NCTR Research Highlights
- 2015-NCTR Research Highlights
- 2014-NCTR Research Highlights [ARCHIVED]
- 2013-NCTR Research Highlights [ARCHIVED]
- 2012-NCTR Research Highlights [ARCHIVED]
- 2011-NCTR Research Highlights [ARCHIVED]
- 2010-NCTR Research Highlights [ARCHIVED]
- 2009-NCTR Research Highlights [ARCHIVED]
- 2008-NCTR Research Highlights [ARCHIVED]
- 2007-NCTR Research Highlights [ARCHIVED]
- 2006-NCTR Research Highlights [ARCHIVED]
Contact FDA
870-543-7000
National Center for Toxicological Research
Food and Drug Administration
3900 NCTR Road
Jefferson, AR 72079
No hay comentarios:
Publicar un comentario